![mdt stock forecast mdt stock forecast](https://static.seekingalpha.com/uploads/2014/9/22/saupload_50a318a6e54ff7b3bd2930b442fab265.png)
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. The company was founded in 1949 and is headquartered in Dublin, Ireland. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures and therapies for vasculature in and around the brain. The Neuroscience Portfolio segment offers products for spinal surgeons neurosurgeons neurologists pain management specialists anesthesiologists orthopedic surgeons urologists urogynecologists interventional radiologists ear, nose, and throat specialists and systems that incorporate energy surgical instruments. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases.
![mdt stock forecast mdt stock forecast](https://investorplace.com/wp-content/uploads/2018/02/MDT.png)
It also provides aortic valves percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices AF ablation products insertable cardiac monitor systems mechanical circulatory support TYRX products and remote monitoring and patient-centered software. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. Looking at the stock’s medium term indicators we note that it is averaging as a 100 Sell, while an average of long term indicators are currently assigning the stock as 50 Sell. Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. On the technical perspective front, indicators give MDT a short term outlook of 100 Sell on average.